11/21
08:27 am
rlyb
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 [Yahoo! Finance]
Low
Report
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 [Yahoo! Finance]
11/21
08:00 am
rlyb
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Low
Report
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
11/8
02:32 pm
rlyb
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
11/7
08:00 am
rlyb
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
Low
Report
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/30
09:25 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/29
08:00 am
rlyb
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
Medium
Report
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
10/24
03:23 pm
rlyb
PhotonPharma Inc. Appoints Derek Brown as New CEO [Yahoo! Finance]
Medium
Report
PhotonPharma Inc. Appoints Derek Brown as New CEO [Yahoo! Finance]
10/1
08:01 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
9/30
08:00 am
rlyb
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
Medium
Report
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
9/23
08:00 am
rlyb
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Neutral
Report
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
9/10
08:00 am
rlyb
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
Neutral
Report
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
9/9
05:15 pm
rlyb
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
Neutral
Report
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
9/3
08:04 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
8/29
08:00 am
rlyb
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
Low
Report
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
8/27
08:00 am
rlyb
Rallybio to Present at Upcoming Investor Conferences
Medium
Report
Rallybio to Present at Upcoming Investor Conferences
8/26
10:09 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "outperform" rating re-affirmed by analysts at Evercore ISI. They now have a $15.00 price target on the stock.
Low
Report
Rallybio Co. (NASDAQ: RLYB) had its "outperform" rating re-affirmed by analysts at Evercore ISI. They now have a $15.00 price target on the stock.